Update to SARS Case Definition Reduces U.S. Cases by Half
WASHINGTON, D.C. and ATLANTA -- The Centers for Disease Control and Prevention (CDC) has dropped the number of SARS cases in the United States by half (49.5 percent) to a total of 211.
The new tally, reported in today's Morbidity and Mortality Weekly Report (MMWR), includes 175 suspect cases and 36 probable cases, down from 344 suspect and 74 probable cases reported on July 15, 2003. The change results from excluding cases that had blood specimens collected greater than 21 days after illness onset test negative for SARS-associated coronavirus (SARS-CoV). Exclusion of these cases with negative convalescent serum provides a more accurate accounting of the epidemic in the US.
The Council of State and Territorial Epidemiologists, an association of public health professionals in US states and territories, recommended the change in the US SARS case definition to allow for exclusion of cases with negative convalescent serum specimens. This recommendation is based on scientific data that indicate 95 percent of SARS patients mount a detectable convalescent antibody response.
Additionally, today's MMWR recommends changing the timing of collection of convalescent-phase serum specimens to test for antibody to SARS-CoV from greater than 21 days to greater than 28 days after the onset of illness. This recommendation comes following analysis of recent data that indicate that some persons with SARS-CoV infection may not mount a detectable antibody response until 28 days after the onset of illness. However, testing results from serum previously collected between 22 and 28 days is acceptable and will not require collection of an additional sample greater than 28 days.
CDC lifted all travel alerts related to SARS between July 1 and15. With removal of all SARS travel alerts and completion of an incubation period (10 days), U.S. travelers with respiratory illness will no longer meet the current case definition for SARS. Reports of suspect or probable cases, therefore, are expected to end by July 31, 2003.
Source: CDC
Ensuring Safety and Comfort: The Urgent Need for Well-Fitted PPE in Health Care
April 5th 2024Personal protective equipment (PPE) stands as the first line of defense against infectious diseases in health care. Yet, the issue of ill-fitting PPE, especially for women, remains a significant challenge.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
